Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NVCT
stocks logo

NVCT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.300
-16.67%
--
--
0.000
-100%
--
--
0.000
-100%
Estimates Revision
The market is revising No Change the revenue expectations for Nuvectis Pharma, Inc. (NVCT) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 0.97%.
EPS Estimates for FY2025
Revise Upward
up Image
+26.7%
In Past 3 Month
Stock Price
Go Up
up Image
+0.97%
In Past 3 Month
Wall Street analysts forecast NVCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVCT is 15.67 USD with a low forecast of 10.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast NVCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVCT is 15.67 USD with a low forecast of 10.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.745
sliders
Low
10.00
Averages
15.67
High
20.00
Current: 6.745
sliders
Low
10.00
Averages
15.67
High
20.00
H.C. Wainwright
Buy
downgrade
$15 -> $10
2025-08-04
Reason
H.C. Wainwright
Price Target
$15 -> $10
2025-08-04
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Nuvectis Pharma to $10 from $15 and keeps a Buy rating on the shares. The firm removed NXP800 from its projections. The deprioritization of NXP800 allows Nuvectis to better deploy capital in assets with a greater chance of success in the clinic, the analyst tells investors in a research note.
Maxim Group
Naz Rahman
Strong Buy
Initiates
$17
2025-04-02
Reason
Maxim Group
Naz Rahman
Price Target
$17
2025-04-02
Initiates
Strong Buy
Reason
Maxim initiated coverage of Nuvectis Pharma with a Buy rating and $17 price target.
Laidlaw & Co.
Yale Jen
Strong Buy
Initiates
$19
2025-03-17
Reason
Laidlaw & Co.
Yale Jen
Price Target
$19
2025-03-17
Initiates
Strong Buy
Reason
Laidlaw analyst Yale Jen initiated coverage of Nuvectis Pharma with a Buy rating and $19 price target. Nuvectis is an early to mid-clinical stage oncology emphasized biotech company that focuses on two novel and first-in-class therapies, the analyst tells investors in a research note. The firm says the company's lead product, NXP900, could find potential use as monotherapy for treating multiple squamous carcinomas.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Nuvectis Pharma Inc (NVCT.O) is -5.52, compared to its 5-year average forward P/E of -6.95. For a more detailed relative valuation and DCF analysis to assess Nuvectis Pharma Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.95
Current PE
-5.52
Overvalued PE
-4.24
Undervalued PE
-9.65

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-6.05
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-3.89
Undervalued EV/EBITDA
-8.22

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

NVCT News & Events

Events Timeline

(ET)
2025-11-04
08:17:11
Nuvectis Pharma Announces Q3 Earnings Per Share of 44 Cents, Exceeding Consensus Estimate of 25 Cents
select
2025-11-04
07:32:45
Nuvectis Pharma Announces Q3 Net Loss of $7.5 Million Compared to $4.2 Million Last Year
select
2025-10-27 (ET)
2025-10-27
08:10:29
Nuvectis Pharma Shares Key Insights from NXP900 Poster Presentations
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-04Newsfilter
Nuvectis Pharma, Inc. Announces Financial Results and Business Highlights for Q3 2025

  • NXP900 Clinical Trials: Nuvectis Pharma has initiated the Phase 1b program for NXP900, focusing on its efficacy in advanced cancers, with the combination therapy expected to start by year-end after successful completion of the Phase 1a study.

  • Financial Overview: The company reported a cash balance of $35.4 million as of September 30, 2025, an increase from the previous year, but also noted a net loss of $7.5 million for the third quarter, attributed to milestone expenses and clinical study costs.

  • Emerging Clinical Profile: NXP900 has shown promising pharmacodynamic responses in clinical studies, supporting its potential as a single agent and in combination therapies to overcome drug resistance in cancer treatment.

  • Future Outlook: Nuvectis aims to leverage its cash position and operational efficiency to achieve key milestones in the NXP900 program, while also considering next steps for another candidate, NXP800, targeting specific cancer types.

[object Object]
Preview
9.5
08-05Newsfilter
Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights

  • NXP900 Drug Development: Nuvectis Pharma's lead drug candidate, NXP900, has successfully completed Phase 1a studies in patients with advanced solid tumors and is set to initiate the Phase 1b program soon. The company also plans to explore NXP800 for potential use in various cancer types.

  • Financial Position Update: As of June 30, 2025, Nuvectis reported a cash position of approximately $39 million following a recent share acquisition, despite a net loss increase to $6.3 million compared to the previous year, primarily due to research and development expenses.

[object Object]
Preview
9.0
07-31Newsfilter
Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study

  • NXP800 Phase 1b Study Results: The Phase 1b study of NXP800 in patients with recurrent, platinum-resistant, ARID1a-mutated ovarian cancer showed 2 partial responses and 3 stable diseases; however, further development in this area will not continue as the company plans to explore other cancer types for NXP800.

  • NXP900 Development Progress: Nuvectis Pharma is set to initiate the Phase 1b program for NXP900 after successfully completing a drug-drug interaction study and a Phase 1a dose escalation study, which demonstrated safety and potential efficacy in advanced solid tumors.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Nuvectis Pharma Inc (NVCT) stock price today?

The current price of NVCT is 6.745 USD — it has increased 5.72 % in the last trading day.

arrow icon

What is Nuvectis Pharma Inc (NVCT)'s business?

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is developing two drug candidates: NXP800 and NXP900. NXP800 is a small molecule GCN2 activator, which is in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP800 activates the GCN2 kinase inducing inhibition of cap-dependent protein translation and activation of the integrated stress response leading to cancer cell death. NXP900 is a targeted-therapy, small molecule drug candidate that inhibits the proto-oncogene c-Src (SRC) and YES1 kinases, which is undergoing a Phase 1a dose escalation study. SRC is aberrantly activated in many cancer types, including solid tumor cancers such as breast, colon, prostate, pancreatic and ovarian cancers.

arrow icon

What is the price predicton of NVCT Stock?

Wall Street analysts forecast NVCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVCT is 15.67 USD with a low forecast of 10.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Nuvectis Pharma Inc (NVCT)'s revenue for the last quarter?

Nuvectis Pharma Inc revenue for the last quarter amounts to -7.79M USD, increased 78.80 % YoY.

arrow icon

What is Nuvectis Pharma Inc (NVCT)'s earnings per share (EPS) for the last quarter?

Nuvectis Pharma Inc. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Nuvectis Pharma Inc (NVCT)'s fundamentals?

The market is revising No Change the revenue expectations for Nuvectis Pharma, Inc. (NVCT) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 0.97%.
arrow icon

How many employees does Nuvectis Pharma Inc (NVCT). have?

Nuvectis Pharma Inc (NVCT) has 13 emplpoyees as of December 05 2025.

arrow icon

What is Nuvectis Pharma Inc (NVCT) market cap?

Today NVCT has the market capitalization of 172.77M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free